

**Trabectedin for the treatment of advanced soft tissue sarcoma**

<http://guidance.nice.org.uk/TA/Wave18/26>

Dear Consultees and commentators,

The Appraisal Committee met on 4th August to discuss the comments received on the ACD for this appraisal.

Following the meeting, the manufacturer of trabectedin submitted a Patient Access Scheme. The Evidence Review Group will now critique the manufacturer's assessment of the effect of this scheme.

The Appraisal Committee will then discuss this appraisal at their meeting on Tuesday 3rd November.

If you have any questions, please contact me.

Best wishes,

Jeremy

**Jeremy Powell**

Technology Appraisal Project Manager

National Institute for Health and Clinical Excellence

MidCity Place | 71 High Holborn | London WC1V 6NA | United Kingdom

Tel: 44 (0)20 7045 2248 | Fax: 44 (0)20 7061 9830